The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), is excited to introduce its groundbreaking inaugural certification program in Natural Killers (NK) and CAR-T (Chimeric Antigen Receptor Tcell) Cells. This two-day hands-on training program, led by Dr.Hassan Bennani, an expert in the application of NK and CAR-T Cells, is designed to equip physicians with advanced skills in anti-aging, immune system support, and advanced cancer therapy. The first-ever course offering by ISSCA will take place on May 12th and 13th in Jakarta, Indonesia.
Importance of NK and CAR-T Cell Therapies
NK cells, the vital type of white blood cells, play a significant role in the innate immune system. Autologous Enriched NK cell therapy has demonstrated the potential to directly attack and destroy abnormal cells. Mesenchymal Stem Cells (MSCs) are another crucial stem cell type that maintain cell balance, replace damaged or dying cells, and can potentially regenerate damaged tissue under pathological conditions. CAR-T cell therapy is a groundbreaking immunotherapy that uses the patient’s own Tcells to recognize and eliminate certain cancers.
Program Content and Structure
The certification program offered by ISSCA gives physicians comprehensive guidance and hands-on practice in collecting tissue samples, using laboratory equipment, processing and isolating various cellular products, and administering treatment to patients. The program encompasses cell culture basics, quality control tests, stem cell processing and regulations in a certified facility, implementation of regulatory and clinical guidelines, clinical procedures, and case protocols for different indications.
Benefits of the ISSCA Certification Program
The ISSCA Certification Program in Natural Killers and CAR-T Cells is expected to offer a wide array of benefits to participating physicians, ultimately enabling them to provide exceptional care to their patients. The advantages of this groundbreaking certification program include:
Access to cutting-edge therapies: The program focuses on NK and CAR-T cell therapies, which have demonstrated significant potential in anti-aging, immune system support, and advanced cancer therapy. Physicians participating in this program will learn how to apply these state-of-the-art therapies to enhance patient outcomes.
Comprehensive training: The two-day hands-on training program, led by Dr. Hassan Bennani, is expected to offer physicians detailed instruction on various aspects of cell therapies, from collecting tissue samples and using laboratory equipment to processing and isolating cellular products.
Adherence to regulatory and clinical guidelines: The program emphasizes the importance of implementing regulatory and clinical guidelines in a certified facility and is expected to ensure that physicians can deliver safe, effective, and compliant treatments to their patients.
Customized clinical protocols: The ISSCA Certification Program covers case protocols for various indications and is expected to enable physicians to develop personalized treatment plans tailored to their patients’ specific needs.
Enhanced professional credibility: By obtaining certification from the reputable International Society for Stem Cell Application, physicians may bolster their professional credibility and showcase their commitment to providing the highest standard of care in the field of regenerative medicine.
Increased practice growth opportunities: Physicians equipped with the skills and knowledge gained through the ISSCA Certification Program are expected to be better positioned to incorporate these advanced therapies into their practice, potentially attracting more clients seeking innovative solutions.
Networking and collaboration: The program provides a platform for physicians to connect with like-minded professionals in the field of regenerative medicine, and is expected to facilitate the exchange of ideas, knowledge, and experiences.
Continuing education and support: As part of the ISSCA community, certified physicians will have access to ongoing educational resources, research updates, and support to help them stay at the forefront of regenerative medicine advancements.
The ISSCA Certification Program in NK and CAR-T Cells is expected to empower physicians with the tools, knowledge, and resources necessary to integrate these innovative therapies into their practice, elevating patient care and enhancing professional growth.
Target Audience and Relevance
This innovative certification program is aimed at doctors seeking training, products, and equipment in regenerative medicine, regardless of their prior experience. It is particularly relevant for doctors interested in staying up-to-date with the latest technologies and protocols, those caring for patients with conditions treatable with cell therapies, and aesthetic doctors. The program caters to doctors with interests in new research on stem cells, MSCs, exosomes, regenerative medicine and medical networks.
ISSCA at Global Perspective
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
